“The PI 3-Kinase and AKT Signaling Pathway in Biology and Disease: From Discovery to Therapeutics”

Alex Toker, Ph.D.
Professor of Pathology, Harvard Medical School
Chief, Division of Signal Transduction
Associate Director, Cancer Research Institute
Beth Israel Deaconess Medical Center,
Investigator, Ludwig Center at Harvard

At the conclusion of this activity, the participant will be able to:

1. Understand the primary mechanisms that control PI3-kinase and AKT signaling in cancer, at the genetic level
2. Learn about the current therapeutic opportunities and drugs used to target PI3K and AKT in the clinic
3. Understand the challenges and limitations of targeting the PI3K/AKT/MTOR pathway in cancer